



APASL STC 2026 Kumamoto
Program at a Glance

Day 1 September 18 (Friday) 2026

	Room 1	Room 2	Room 3	Poster
	Registration			
08:50-09:00	8:50-9:00 Opening Remarks			
09:00-09:10	9:00-9:20 State of the Art Lecture I Dr. Chien-Jen Chen	9:00-9:20 State of the Art Lecture III Dr. Hiroyoshi Nishikawa	9:00-10:20 Session 4 Cutting Edge in Basic Research of Steatotic Liver Diseases (MASLD/MAFLD and ALD)	
09:10-09:20				
09:20-09:30	9:20-9:40 State of the Art Lecture II Dr. Kiyohiko Izumi			
09:30-09:40		9:20-10:40 Session 2 Cutting Edge in Liver Cancer Research: Molecular Mechanisms and Therapeutic Targets		
09:40-09:50				
09:50-10:00				
10:00-10:10	9:40-11:10 Session 1 Ending Viral Hepatitis in Asia: Current Challenges and Future Perspectives			
10:10-10:20				
10:20-10:30				
10:30-10:40				
10:40-10:50				
10:50-11:00				
11:00-11:10				
11:10-11:20				
11:20-11:30	11:20-11:50 Keynote Lecture I Dr. Jia-Horng Kao	10:50-12:20 Session 3 Advances in the Epidemiology and Diagnosis of Hepatocellular Carcinoma	10:30-12:20 Session 5 Cutting-Edge Advances in the Epidemiology and Diagnosis of MASLD/MAFLD	
11:30-11:40				
11:40-11:50				
11:50-12:00	11:50-12:20 Keynote Lecture II Dr. Makoto Nakanishi			
12:00-12:10				
12:10-12:20				
12:20-12:30				
12:30-12:40				
12:40-12:50	12:30-13:30 Luncheon Seminar 1 [Gilead Sciences K.K.]	12:30-13:30 Luncheon Seminar 2 [Chugai Pharmaceutical Co., Ltd.]	12:30-13:30 Luncheon Seminar 3 [Boehringer Ingelheim GmbH]	
12:50-13:00				
13:00-13:10				
13:10-13:20				
13:20-13:30				
13:30-13:40				
13:40-13:50		13:40-13:55 Special Lecture Dr. Masao Omata	13:40-14:10 Plenary Session	
13:50-14:00	13:40-14:10 Keynote Lecture III Dr. Hiroaki Mitsuya	13:55-14:15 State of the Art Lecture IV Dr. Jacob George		
14:00-14:10				
14:10-14:20			14:10-15:30 IASL-APASL STC Joint Symposium: HBV Diagnosis and Treatment in Asia: From Biomarkers to the Indeterminate Grey Zone and HCC Management	
14:20-14:30	14:10-15:30 Session 6 Cutting Edge in HBV Research: From Basic Virology to Pathogenesis	14:15-15:30 Session 8 Future Directions in the Management of MASH: Integrating Emerging and Novel Therapeutic Strategies		
14:30-14:40				
14:40-14:50				
14:50-15:00				
15:00-15:10				
15:10-15:20				
15:20-15:30				
15:30-15:40				
15:40-15:50				
15:50-16:00	15:45-16:45 Sponsored Seminar 1 [GlaxoSmithKline K.K.]	15:45-16:45 Sponsored Seminar 2 [AbbVie GK]	15:45-16:45 Sponsored Seminar 3 [Fujirebio, Inc.]	
16:00-16:10				
16:10-16:20				
16:20-16:30				
16:30-16:40				
16:40-16:50				
16:50-17:00				
17:00-17:10	16:55-17:55 Session 7 Novel Biomarkers in HBV: Clinical Utility and Future Prospects	16:55-18:10 Session 9 HCV-Related HCC in the Post-SVR Era: Risk Assessment and Surveillance	16:55-17:55 Evening Seminar [Eisai Co., Ltd.]	
17:10-17:20				
17:20-17:30				
17:30-17:40				
17:40-17:50				
17:50-18:00				
18:00-18:10				
18:10-18:20				
18:20-18:30			18:05-18:40 Free Papers 1 HBV	
18:30-18:40				
18:40-18:50				
18:50-19:00				
19:00-19:10	19:00-21:00 Awarding Ceremony Welcome Reception			
19:10-19:20				
19:20-19:30				
19:30-19:40				
19:40-19:50				
19:50-20:00				
20:00-20:10				
20:10-20:20				
20:20-20:30				
20:30-20:40				
20:40-20:50				
20:50-21:00				

*The program is subject to change.



APASL STC 2026 Kumamoto
Program at a Glance

Day 2 September 19 (Saturday) 2026

	Room 1	Room 2	Room 3	Poster	
08:00-08:10	08:00-9:00 Morning Seminar 1 [Taisho Pharmaceutical Co., Ltd.]	08:00-9:00 Morning Seminar 2 [Fujirebio, Inc.]	08:00-9:00 Morning Seminar 3 [Miyarisan Pharmaceutical Co., Ltd.]		
08:10-08:20					
08:20-08:30					
08:30-08:40					
08:40-08:50					
08:50-09:00					
09:00-09:10				Poster Viewing	
09:10-09:20	09:10-9:30 State of the Art Lecture V Dr. Masatoshi Kudo	09:10-10:40 Session 11 Current Standards and Controversies in the Management of Chronic Hepatitis B	09:10-10:20 Free Papers 2 Liver Cancer: Clinical Practice and Systemic Therapy		
09:20-09:30					
09:30-09:40	09:30-11:00 Session 10-1 Reconstructing the Treatment Landscape of Hepatocellular Carcinoma Through Systemic Therapy				
09:40-09:50					
09:50-10:00					
10:00-10:10					
10:10-10:20					
10:20-10:30					
10:30-10:40			10:30-10:50 State of the Art Lecture VI Dr. Takahiro Ochiya		
10:40-10:50					
10:50-11:00	10:50-12:20 Session 12 Novel Therapies for HBV: The Road to Functional Cure	10:50 -12:20 Session 13 Cutting Edge in Cirrhosis Research: Mechanisms of Regeneration and Fibrosis Reversal			
11:00-11:10					
11:10-11:20			11:10-12:20 Session 10-2 Reconstructing the Treatment Landscape of Hepatocellular Carcinoma Through Systemic Therapy		
11:20-11:30					
11:30-11:40					
11:40-11:50					
11:50-12:00					
12:00-12:10					
12:10-12:20					
12:20-12:30	12:30-13:30 Luncheon Seminar 4 [GlaxoSmithKline K.K.]	12:30-13:30 Luncheon Seminar 5 [ONO PHARMACEUTICAL CO., LTD./ Bristol-Myers Squibb K.K.]	12:30-13:30 Luncheon Seminar 6 [Roche Diagnostics K.K.]		
12:30-12:40					
12:40-12:50					
12:50-13:00					
13:00-13:10					
13:10-13:20					
13:20-13:30					
13:30-13:40	13:40-14:10 Keynote Lecture IV Dr. Shiv K. Sarin	13:40-15:00 Session 15 Frontiers of Conversion Therapy for Advanced Hepatocellular Carcinoma	13:40-14:40 Session 16 Cutting Edge in Autoimmune Liver Disease (PBC/AIH/PSC): From Basic Science to Clinical Practice		
13:40-13:50					
13:50-14:00					
14:00-14:10			14:15-15:35 Session 14 Cutting-Edge Advances in the Management of Cirrhosis and Portal Hypertension: Insights from Baveno Consensus	14:40-15:10 Free Papers 4 HCC: Basic & Translational	
14:10-14:20					
14:20-14:30					
14:30-14:40	15:00-15:30 Free Papers 3 Surgery, Biliary Diseases, and Other Topics				
14:40-14:50					
14:50-15:00					
15:00-15:10					
15:10-15:20					
15:20-15:30					
15:30-15:40			Poster Session 15:00-17:00		
15:40-15:50	15:45-16:45 Sponsored Seminar 4 [Gilead Sciences K.K.]	15:45-16:45 Sponsored Seminar 5 [AbbVie GK]		15:45-16:20 Free Papers 5-1 MASLD/ALD 1	
15:50-16:00					
16:00-16:10				16:20-17:00 Free Papers 5-2 MASLD/ALD 2	
16:10-16:20					
16:20-16:30				16:50-17:20 Free Papers 6 Cirrhosis	16:50-17:25 Free Papers 7 Liver Cancer: Detection and Risk Stratification
16:30-16:40					
16:40-16:50					
16:50-17:00					
17:00-17:10					
17:10-17:20					
17:20-17:30					
17:30-17:40	17:30-17:40 Closing Remarks				
17:40-17:50					
17:50-18:00					

*The program is subject to change.